MedTrace Logo

IL- 6 Gene (174G/C) Single Nucleotide Polymorphism as an Indicator of COVID-19 Severity in Egyptian Patients

NCT04544033 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2022-05-03

No results posted yet for this study

Summary

Although the direct damage from the viruses contributes to the initiation of the disease, the cytokine storm caused by COVID-19 plays a vital role in the development of acute lung injury and adult respiratory distress syndrome. IL-6, a kind of pleiotropic cytokine, is expressed by immune cells such as DC, monocytes, macrophages, B cells, and subsets of activated T cells, as well as by non-immune cells like fibroblasts, epithelial cells, and keratinocytes

Conditions

  • Covid19

Interventions

DIAGNOSTIC_TEST

interleuken 6 level measurment

Detection of IL6 level using ELISA technique.

DIAGNOSTIC_TEST

Interleukin-6 Gene-174C detection

The genotyping of the polymorphisms in IL-6 promoter G-174C (rs1800795) will be performed using PCR-RFLP technique.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-15
Primary Completion
2022-03-15
Completion
2022-05-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04544033 on ClinicalTrials.gov